Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary

Incannex Healthcare (Nasdaq: IXHL) priced a registered direct offering to raise approximately $10.0 million by issuing 2,000,000 common shares and accompanying warrants at a combined purchase price of $5.00 per share, expected to close on or about March 13, 2026.

If all warrants are exercised for cash at an exercise price of $6.50, Incannex could receive up to an additional $13.0 million, bringing total potential gross proceeds to about $23.0 million. Proceeds are expected to fund completion of the DReAMzz Phase 2 study for IHL-42X and for working capital; the company has terminated its ATM facility.

Positive

• Registered direct offering to raise $10.0M gross proceeds
• Potential additional $13.0M if all warrants are exercised
• Proceeds expected to fund completion of DReAMzz Phase 2 for IHL-42X
• Current cash expected to remain available for Phase 3 development

Negative

• Issuance of 2,000,000 shares will dilute existing shareholders
• Warrant exercise could further dilute shareholders by up to 2,000,000 shares
• Termination of the ATM facility reduces near-term equity financing flexibility

News Market Reaction – IXHL

-48.41% 9.5x vol

68 alerts

-48.41% Session close to close

+3.3% Peak Tracked

-56.7% Trough Tracked

$71.31M Market Cap

9.5x Rel. Volume

In the Mar 12 session, IXHL declined 48.41%, reflecting a significant negative market reaction. Argus tracked a peak move of +3.3% during that session. Argus tracked a trough of -56.7% from its starting point during tracking. Our momentum scanner triggered 68 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 9.5x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -48.4% in the session following this news. A negative reaction despite the at-the-...

Analysis

The stock dropped -48.4% in the session following this news. A negative reaction despite the at-the-market-priced $10.0M offering would fit prior sensitivity to capital structure moves, such as the -42.12% response to the reverse split. While the company expects proceeds to complete the DReAMzz Phase 2 study for IHL-42X, investors may focus on dilution and its history of equity financing. Sustainability of any move would likely hinge on future clinical milestones and cash usage discipline.

Key Figures

Shares offered: 2,000,000 shares Offering price: $5.00 per share Gross proceeds at close: $10.0 million +5 more

8 metrics

Shares offered 2,000,000 shares Common stock or equivalents in registered direct offering

Offering price $5.00 per share Combined purchase price per share and accompanying warrant

Gross proceeds at close $10.0 million Aggregate gross proceeds from registered direct offering

Warrant proceeds potential $13.0 million Additional gross proceeds if common warrants fully exercised for cash

Total potential proceeds $23.0 million Gross proceeds including offering and full warrant exercise

Warrant exercise price $6.50 per share Exercise price of common warrants issued in financing

Warrant expiry March 13, 2031 Expiration of common warrants at 5:00 p.m. New York time

Stock equivalent exercise price $0.0001 Exercise price of common stock equivalents issued in offering

Historical Context

5 past events · Latest: Feb 25 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 25	Reverse stock split	Negative	-42.1%	1-for-30 reverse split to regain Nasdaq minimum bid compliance.
Feb 18	Clinical data & cash	Positive	+8.3%	Phase 2 IHL-42X data and liquidity update including $68.9M cash.
Jan 29	Board additions	Positive	-0.6%	Three new Clinical Advisory Board members to guide PSX-001 program.
Jan 22	CAB formation	Positive	+0.5%	New Clinical Advisory Board established for PSX-001 anxiety program.
Jan 15	R&D award	Positive	-1.7%	Award for IHL-42X obstructive sleep apnea development in 2025 awards.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news tied to financing structure and corporate recognition has produced mixed reactions, with large downside on structural actions and smaller, inconsistent moves on positive clinical and corporate updates.

Recent Company History

Over recent months, Incannex has combined financing and corporate actions with clinical progress. A 1-for-30 reverse split on Feb 25, 2026 led to a -42.12% move. Coverage on IHL-42X’s Phase 2 results and liquidity on Feb 18 coincided with an 8.27% gain. Clinical Advisory Board formations in January produced only minor moves, while an R&D award on Jan 15 saw a modest decline. Today’s registered direct offering adds another capital-raising step to that trajectory.

Key Terms

registered direct offering, at-the-market facility, atm financing, common warrants, +4 more

8 terms

registered direct offering financial

"Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

at-the-market facility financial

"Incannex has terminated its at-the-market facility and does not intend to utilize ATM financing"

An at-the-market facility is a standing arrangement that lets a publicly traded company sell new shares directly into the open market at whatever the current market price is, typically through an investment bank acting as a sales agent. For investors it matters because it provides the company with a flexible way to raise cash without a large, one-time share offering; however, selling additional shares can dilute existing ownership and, by increasing supply, may pressure the stock price like adding more tickets to a limited-seat event.

atm financing financial

"does not intend to utilize ATM financing in the near term"

At-the-market (ATM) financing is a way for a public company to raise money by selling newly issued shares directly into the open market at the prevailing market price, often in small amounts over time through a broker. It matters to investors because it can dilute existing ownership and affect share price, but it gives the company flexibility to raise capital as needed without a large, single stock sale—similar to restocking and selling items gradually at current store prices.

common warrants financial

"accompanying common warrants to purchase up to an aggregate of 2,000,000 shares"

A common warrant is a tradable instrument that gives its holder the right to buy a company’s common shares at a fixed price within a set time period, similar to a coupon that can be redeemed later to purchase stock. Investors care because exercising warrants can boost potential gains if the stock rises, but it can also dilute existing shareholders by increasing the number of shares outstanding, which can lower per-share value.

common stock equivalents financial

"common stock (or common stock equivalents in lieu thereof) and accompanying common warrants"

Common stock equivalents are financial instruments that can be converted into common shares or have a similar effect on a company's stock ownership, such as stock options or convertible bonds. They matter to investors because they can increase the total number of shares outstanding, potentially diluting existing ownership and affecting the company's stock value. Recognizing these equivalents helps investors understand the true potential for future share issuance and company ownership structure.

placement agent financial

"Curvature Securities LLC is acting as the sole placement agent for the offering"

A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.

form s-3 regulatory

"offered pursuant to a registration statements on Form S-3 (File Nos. 333-283028 and 333-288921)"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"The offering is being made only by means of a prospectus supplement which is a part"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK and MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IHXL), ("Incannex" or the “Company") a clinical-stage biopharmaceutical company leading the way in developing combination medicines, today announced that it has entered into a securities purchase agreement with healthcare-dedicated institutional investors for the issuance and sale of 2,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and accompanying common warrants to purchase up to an aggregate of 2,000,000 shares of its common stock at a combined purchase price of $5.00 per share and accompanying common warrants. The financing is expected to generate aggregate gross proceeds of approximately $10.0 million at closing. If the common warrants issued in the financing are exercised in full for cash, the Company would receive up to an additional $13.0 million in gross proceeds, for total potential gross proceeds of approximately $23.0 million. The offering is expected to close on or about March 13, 2026, subject to the satisfaction of customary closing conditions.

Based on current projections, Incannex believes the proceeds from the offering will be sufficient to complete the DReAMzz Phase 2 study for IHL-42X. The Company’s current cash on hand, prior to closing this financing, is expected to remain available for Phase 3 development and is not expected to be used until Phase 3 begins, which is anticipated in the second half of 2027. Additionally, Incannex has terminated its at-the-market facility and does not intend to utilize ATM financing in the near term.

Each common warrant will be exercisable for one share of common stock at an exercise price of $6.50 per share, will be immediately exercisable, and will expire on 5:00 p.m. (New York City time) on March 13, 2031. The common stock equivalents have an exercise price of $0.0001, are immediately exercisable and expire when exercised in full. The gross cash proceeds from the offering, before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be approximately $10 million. The Company expects to use the net proceeds from the offering for working capital, which will include research and development expenses, clinical trial expenses and general corporate purposes.

Curvature Securities LLC is acting as the sole placement agent for the offering.

The shares and common stock equivalents offered to the institutional investors described above are being offered pursuant to a registration statements on Form S-3 (File Nos. 333-283028 and 333-288921), which were filed with the Securities and Exchange Commission (the “SEC”) on November 22, 2024 and July 24, 2025, respectively. The offering is being made only by means of a prospectus supplement which is a part of the effective registration statement. A final prospectus supplement and the accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Additionally, when available, electronic copies of the final prospectus supplement and the accompanying base prospectus may be obtained from Curvature Securities LLC, 39 Main Street, Chatham, NJ 07928, or by telephone at (908) 944-9400, or by email at IB@curvaturesecurities.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Incannex Healthcare Inc. 

Incannex is leading the way in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. The Company is advancing three clinical-stage product candidates based on evidence-based innovation and supported by streamlined operations. Incannex's lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnea. In a Phase 2 development program, IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. Approved for Phase 2 clinical development, PSX-001 is an oral synthetic psilocybin treatment for the treatment of generalized anxiety disorder. Incannex's programs target disorders that have limited, inadequate, or no approved pharmaceutical treatment options. For additional information on Incannex, please visit our website at www.incannex.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the expected closing date, the satisfaction of customary closing conditions related to the offering, the anticipated use of proceeds from the offering, the sufficiency of these proceeds to fund the DReAMzz Phase 2 study for IHL-42X, whether the Company’s current cash on hand will remain available to fund Phase 3 development and expectations regarding its use, the timing and future development of the Company’s drug candidates, including the anticipated timing for a Phase 3 clinical trial, and the Company’s ability to fund its operations without utilizing an at-the-market facility in the near term. When or if used in this communication, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company, its operations or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the risk that the offering may not close, the risk that the Company’s estimates and current projections regarding the sufficiency of the proceeds of the offering and its current cash on hand to fund the Company’s planned operations may be incorrect and the Company may use these resources faster than anticipated, the risk that the common warrants may not be exercised or may not be exercised in cash, and other risks described in the section entitled "Risk Factors" described in the prospectus supplement and in the Company's annual report on Form 10-K for the fiscal year ended June 30, 2025, filed with the SEC on September 29, 2025, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, which can be obtained on the SEC website at www.sec.gov and are made available on the Company’s website upon their filing with the SEC. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Investor & Media Contacts
CORE IR
(212) 655-0924
investors@incannex.com
media@incannex.com.au

FAQ

What is Incannex (IXHL) selling in the March 2026 registered direct offering?

Incannex is selling 2,000,000 common shares with accompanying warrants at a combined price of $5.00 per share. According to the company, the offering is expected to close on or about March 13, 2026, subject to customary closing conditions.

How much gross capital will Incannex (IXHL) raise from the offering and warrants?

The offering is expected to generate approximately $10.0 million in gross proceeds at closing. According to the company, full warrant exercise would add up to $13.0 million, for total potential gross proceeds of about $23.0 million.

How will the March 2026 financing affect Incannex (IXHL) clinical programs?

Proceeds are expected to fund completion of the DReAMzz Phase 2 study for IHL-42X. According to the company, existing cash on hand is expected to remain available for Phase 3 development planned for the second half of 2027.

What are the key terms of the warrants issued to investors in the offering by Incannex (IXHL)?

Each common warrant is exercisable for one share at an exercise price of $6.50 and expires March 13, 2031. According to the company, the warrants are immediately exercisable and will expire at 5:00 p.m. New York City time on that date.

Will Incannex (IXHL) continue using its ATM facility after this financing?

No, Incannex has terminated its at-the-market (ATM) facility and does not intend to use ATM financing in the near term. According to the company, the ATM termination reduces reliance on continuous equity sales going forward.